# Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer

> **Newsylist Open Intelligence Dossier** · First detected: 2026-10-23 16:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Intelligence Brief
"Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer" developed substantial multi-source reporting across the Business sector, tracked across 5 distinct newsrooms by Newsylist.


Key reporting was led by Investing.com Canada, BioSpace, Targeted Oncology and Endpoints News. Coverage velocity and cross-outlet momentum were measured using Newsylist open coverage telemetry.


Synthesized from multi-source international reporting and live coverage telemetry under Newsylist open intelligence methodology.

## Verified Facts & Key Claims
### What drove coverage for Tango reports 82% tumor response rate in trial of combo therapy for advance?
Coverage spiked when 5 independent newsrooms published 5 verified reports during this coverage cycle.

### How did Newsylist track this trend?
Newsylist monitored article arrival rates, source diversity, and cross-outlet validation in real time.

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Investing.com Canada | Form 8K Tango Therapeutics Inc For: 23 October By Investing.com | 2026-10-23 10:34 | [Source Link](https://news.google.com/rss/articles/CBMiqgFBVV95cUxOUlVJeHhHRHFqWGpCcUJYdnpPdXU2X3ctNk9PQ3RtVlFucDh5Slo0RDFjdXR2YXNJZWVXLUc5c3lHdXY0aXg2VUVMdU1RclNzaHlrYUNTam1Zekp5RHZxVERNd0VhN1Q4S0tteTNNWVh3ckNxemhOTXZoYmU0TVM2dTJ1X2FaSDd2Q1QzR3VJc2VVN0E1bkJCbzBwWmFSMEx0OWZ2dDNYWVdBUQ?oc=5) |
| BioSpace | ESMO 2026: Tango trips on sinking response rates in pancreatic cancer but will move to Phase 3 | 2026-10-23 10:34 | [Source Link](https://news.google.com/rss/articles/CBMi0AFBVV95cUxPU2Q2aUttMlRDVnFIM3czd3RCQXBaUmhIUlFtZ09oaDZhazl3NWlKajR2TXBsdjROZFNrMUVSZXItbzVyVkR1RG4xT2MzTXBGVlNXS3lfWHFiX2xwS0d4SGFMZUlrdVZER0tQdWdvbVhkRF9OSFFIYl9OajN6RzliOTFnM0oybDJVanVqNDVUQjRUb2FFV25RaURDbnRGTUlUWjk4ejJtZmd3VVM2OC1KNEg4ekhneHpNX1VsQU5zZ2ZMNnlUeFBWcmhWSFFwZllr?oc=5) |
| Targeted Oncology | Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC | 2026-10-23 10:34 | [Source Link](https://news.google.com/rss/articles/CBMinwFBVV95cUxNSFB3Z0Y2b2JQZzNWTmc4RDBVMXNabE5yZ2RvczFMRnU3R2p5RUd3SDJmb2lVYjhXQUQ3NXhNSWNwM01lNVN6NkdUY0VRY2tvOTRMLXc3NDVpYzVSNDZBRm84b0U3SjFVQVNMVnkzWmt5MTM1YWRObXdJY0d2UmpnRTMxMWlMVHlkSEZnUGlZWW5lODFGN3VKNlJESkNIQWc?oc=5) |
| Endpoints News | Tango combo clears Rasonque bar, Takeda’s Innovent bet gets early returns, plus more from #ESMO26 | 2026-10-23 10:34 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxNRFFBaXIydEczblV6T2x3Xy1jNGI2VEFDYW8xZmpnMDBnQUlpOWVtbXpmallCT2txdGd1OE4wdnZNUjdvTmpoMVVPRUFfdXhROVp6YUVuM24xdHJWTkx6ZGRxM2ZzdGZKeFl6NnFuUmdCTlJkdW4xcHI2dDRVOVBnWnNhOTUtQXhQa0t5Zi03MXJCVW44MXFobjVUM2VfQm9MYmlxSDd5QVgyQk9ubEk4RmlQZzdrc0E?oc=5) |
| STAT | Tango reports 82% tumor response rate in trial of combo therapy for advanced pancreatic cancer | 2026-10-23 10:34 | [Source Link](https://news.google.com/rss/articles/CBMivwFBVV95cUxNa0wzR2ZBQ2tGamotM0EwakVKVTMyWFFNVDU2bU56b3lFUm8yalp0UVRTRGtEYm4ta3hwYnNoajNXc015NmViajliN2dWbkw4cHRYbzZnaDVETGVNc3MxblNpUTV2eDFxN3RmZ0wyaVpiUDdIekJyUnR2Z2s3eTJUVWJqNHk2Qlk1d2lwSjJ3dVlIdDdCdjJseDZuN3JCVng4YWt2aVkxZHVTTmFSWXBFZHZDYVpWVHR1cHJEN3RRUQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-10-23/tango-reports-82-tumor-response-rate-in-trial-of-combo-therapy-for-advanced*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*